Evan Sussman: Expanding Access to Fertility Drugs
Subscribe to Health & Veritas on Apple Podcasts, Spotify, YouTube, or your favorite podcast player.
Howie and Harlan welcome Evan Sussman, the CEO of Granata Bio, which aims to bring IVF and fertility drugs that have been proven in other markets to the United States. Harlan reports on Elon Musk’s Neuralink, which will test a technology to restore rudimentary sight to the blind; Howie tries to reconcile conflicting reports about the viability of the Medicare trust fund.
Links:
Neuralink
“Elon Musk announces Neuralink’s first human implant of Blindsight coming this year”
“Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant”
“Elon Musk's Neuralink receives Canadian approval for brain chip trial”
Granata Bio
“Fertility treatment costs are out of reach for many Americans, even with insurance”
“Acceptable cost for the patient and society”
RESOLVE: The National Infertility Association: Insurance Coverage by State
“Politicians say health plans should cover IVF. Currently only 1 in 4 employers do”
“Catching Up with Alumni: The Founders of Granata Bio”
“Trump signs executive order seeking to expand IVF access”
The Medicare Trust Fund
“The Long-Term Budget Outlook: 2025 to 2055”
“Medicare gets a big (unofficial) surprise: a 17-year extension on when it’ll run dry”
“CMS Finalizes 2026 Payment Policy Updates for Medicare Advantage and Part D Programs”
“Health Insurer Stocks Soar on Medicare Rate Boost”
“Insurer-Level Estimates of Revenue From Differential Coding in Medicare Advantage”
Medicare.gov: “How is Medicare funded?”
Learn more about the MBA for Executives program at Yale SOM.